Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RG1145 | Human CXCR2 Stable Cell Line-CHO-K1 | Inquiry |
| CSC-DC003875 | Panoply™ Human CXCR2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC003875 | Panoply™ Human CXCR2 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2631 | Human CXCR2 Knockout Cell Line-HEK293T | Inquiry |
| CSC-RG1832 | Human CXCR2 Stable Cell Line-HCT116 | Inquiry |
| CSC-RG1833 | Human CXCR2 Stable Cell Line-HEK293 | Inquiry |
| CSC-RH0082M | Humanized CXCR2 Murine Tumor Cell Line | Inquiry |
| CSC-RO02496 | Monkey CXCR2 Stable Cell Line - HEK293 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04436Z | Human CXCR2 adenoviral particles | Inquiry |
| LV10097L | human CXCR2 (NM_001557) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHG213135 | shRNA set against Mouse Il8rb(NM_009909.3) | Inquiry |
| SHG213235 | shRNA set against Human IL8RA(NM_000634.2) | Inquiry |
| SHG213253 | shRNA set against Mouse Il8ra(NM_178241.4) | Inquiry |
| SHH272261 | shRNA set against Human CXCR2 (NM_001557.3) | Inquiry |
| SHH272265 | shRNA set against Mouse CXCR2 (NM_009909.3) | Inquiry |
| SHH272269 | shRNA set against Rat CXCR2 (NM_017183.1) | Inquiry |
| SHL176210 | shRNA set against Rat Il8rb(NM_017183.1) | Inquiry |
| SHL176228 | shRNA set against Rat Il8ra(NM_019310.1) | Inquiry |
| SHW004406 | shRNA set against Chicken CXCR2 (NM_001282432) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| OE-PNDC000070 | Human CXCR2 Nanodisc | Inquiry |
| OE-PNDC000838 | Human CXCR2 Nanodisc | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB156760 | Cynomolgus CXCR2 ORF clone | Inquiry |
| CDCL183853 | Mouse CXCR2 ORF clone(NM_009909.3) | Inquiry |
| CDFH004564 | Human CXCR2 cDNA Clone(NM_001168298.1) | Inquiry |
| CDFR011235 | Rat Cxcr2 cDNA Clone(NM_017183.1) | Inquiry |
| MiUTR1M-06021 | CXCR2 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-02657 | CXCR2 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-01165 | CXCR2 miRNA 3'UTR clone | Inquiry |
| CDCB165881 | Chicken CXCR2 ORF Clone (NM_001282432) | Inquiry |
| CDCB180658 | Rabbit CXCR2 ORF clone (NM_001171090.1) | Inquiry |
| CDCL184914 | Human IL8Ra ORF clone(NM_000634.2) | Inquiry |
| CDCL184915 | Rat IL8RA ORF clone(NM_019310.1) | Inquiry |
| CDCL184918 | Rat IL8RB ORF clone(NM_017183.1) | Inquiry |
The CXCR2 gene belongs to the CXC chemokine receptor family and is a seven-transmembrane G protein-coupled receptor first identified in 1991. Particularly in immunological response, CXCR2 is very important in many physiological and pathological mechanisms. Mostly via binding to chemokines including IL-8 (interleukin-8), the protein produced by this gene is a vital regulator of leukocyte migration and inflammatory response, therefore helping to control neutrophil migration and contribute to the development of different disorders.
The CXCR2 receptor protein plays a vital role in immune response through its interaction with various chemokines. By interacting with G proteins, this is a typical G protein-coupled receptor (GPCR) that starts intracellular signaling. Though mostly an IL-8 receptor, CXCR2 may also bind additional CXC chemokines including CXCL1, CXCL2, and CXCL3, therefore setting off a sequence of intracellular biological events.
CXCR2 is expressed in neutrophils, endothelial cells, and tumor cells. Neutrophils travel to inflammatory areas where they serve their immunological surveillance and defense roles upon CXCR2 activation. Under several physiological and pathological states, CXCR2 also shows its wide biological activities in processes like tumor development and angiogenesis.
Located on chromosome 2q34-q35, the CXCR2 gene forms a cluster with the CXCR1 gene. Crucially for CXCR2 expression control, its promoter region has a distinctive TATA box and many transcription factor binding sites including Sp1 and AP-2. Studies reveal many elements influence CXCR2 expression: oxygen levels, intracellular signaling pathways, and transcription factor binding.
In hypoxic conditions, for example, CXCR2 expression is commonly elevated through HIF-1 and NF-κB activation of transcription factors. Certain microRNAs (miRNAs) also control CXCR2 expression by targeting its mRNA, therefore influencing its stability or translation efficiency and hence CXCR2 expression levels.
Figure 1. miRNAs regulate CXCR2 expression. (Korbecki J, et al., 2022)
Extensive research highlights CXCR2's critical role in the immune system, particularly in inflammation. The main immune cells in charge of clearing pathogens during infection and inflammation are neutrophils. With IL-8 as the main natural ligand, CXCR2 helps neutrophils identify infection or damage sites during their migration to infected or inflammatory regions.
Increased CXCR2 expression causes too strong neutrophil migration in chronic inflammatory illnesses like rheumatoid arthritis, asthma, and Crohn's disease, hence aggravating inflammation and tissue damage. Promoting tumor development and metastases within the tumor microenvironment, CXCR2 is also associated with tumor immune evasion.
Recent studies show CXCR2's significance extends beyond inflammation to tumor growth, metastasis, and immune evasion. Lung, liver, and breast malignancies among other types of cancer have elevated CXCR2 expression. CXCR2 draws neutrophils to tumor locations in the tumor microenvironment, hence increasing angiogenesis that fuels and oxygenates tumor development. By means of several tumor-associated chemokines, CXCR2 also improves tumor cell motility and metastases, therefore enabling immune surveillance escape.
CXCR2 is thought to be a target in various cancer therapies. By specifically targeting CXCR2 or its ligands, tumor angiogenesis, metastases, and immune evasion may be sufficiently stopped, hence enhancing anti-tumor treatments. Currently in clinical studies, many small molecule inhibitors aiming at CXCR2 show great potential.
As a G protein-coupled receptor, CXCR2's signaling mechanism is complex. Upon activation, CXCR2 interacts with G proteins to activate downstream pathways. It primarily engages the Gαi protein with pathways like PI3K-Akt and the phosphoinositol-calcium second messenger system, regulating cell migration, proliferation, and differentiation.
G protein βγ subunits are vital in CXCR2 signaling, activating phospholipase C (PLC-β) to promote calcium release, affecting cell movement and function. CXCR2 signaling also involves intracellular protein kinases, like protein kinase C (PKC), crucial for receptor desensitization and internalization processes.
Moreover, CXCR2 interacts with numerous other receptors and molecules beyond single pathways, forming a complex "chemical synapse" that defines CXCR2's functions and mechanisms in different cell types.
CXCR2 gene mutations are closely linked to various diseases. CXCR2 deficiencies or functional abnormalities can lead to immune system disorders, causing immune-related diseases. For instance, CXCR2 knockout mice exhibit severe neutropenia, underscoring CXCR2's role in normal immune functions. Moreover, CXCR2 mutations are associated with congenital immune deficiencies, cancers, and inflammatory diseases.
Specific CXCR2 mutations may alter ligand binding affinity or signaling efficiency, triggering distinct pathological responses. Understanding CXCR2 gene mutations and mechanisms can provide theoretical bases for early diagnosis, treatment, and prevention of related diseases.
CXCR2's pivotal role in numerous diseases presents it as a potential therapeutic target. Strategies focus on inhibiting ligand binding or disrupting its signaling pathways to mitigate CXCR2's adverse effects in inflammation and tumor progression.
For instance, various small molecule CXCR2 antagonists development shown excellent therapeutic results in preclinical research. These antagonists competitively block CXCR2 ligand binding, therefore reducing inflammation and limiting too strong neutrophil migration. Furthermore providing novel cancer therapeutic approaches, CXCR2 antagonists reduce tumor angiogenesis and metastases.
References: